Welcome : Guest

Press Release


MCP-6811: NEXT GENERATION SEQUENCERS – A GLOBAL STRATEGIC BUSINESS REPORT

March 15, 2017 – Declining Cost and Expanding Applications to Drive Market Growth for Next Generation Sequencers, According to New Report by Global Industry Analysts, Inc.

GIA launches comprehensive analysis of industry segments, trends, growth drivers, market share, market size and demand forecasts on the global Next Generation Sequencers market. The global Next Generation Sequencers market is projected to exceed US$4.2 billion by 2022, driven by the growing adoption in an expanded range of applications, reduced cost of genome sequencing, and advent of ultra-high throughput sequencers with improved capabilities.

Since the sequencing of the first human genome a decade ago, the sequencing technology landscape has seen considerable developments, with the introduction of Next Generation Sequencing (NGS) especially transforming the way in which human genomes are sequenced. Next generation sequencing (NGS) is a high-throughput sequencing technology, where innumerable DNA strands are sequenced in parallel that not only yield higher throughput but also reduce the need for fragment-cloning techniques used in Sanger sequencing of genomes. With the success of the Human Genome Project (HGP) in the 1990s, the demand for high-throughput NGS methods has increased rapidly. The reducing cost of sequencing, made possible by evolving technologies, is playing a critical part in expanding applications of NGS technology, thus fuelling demand for NGS sequencers and consumables.

Strong growth is projected for the market in the coming years driven by emerging applications for NGS technologies in areas such as cancer research, biomarker discovery, personalized medicine, agricultural and animal sciences, and drug discovery. Growing world population and increasing incidences of diseases, such as cancer, infectious diseases, pre- and post-natal disorders and inherited rare disorders, are expected to spur application of sequencing data for the diagnosis and prognosis of infectious diseases and oncology. NGS market will be especially fostered by the application of exome and genome sequencing in cancer research for the purpose of companion diagnostics and biomarker development. Furthermore, the growing use of NGS protocols for developing personalized medicine through genetic level-medical analysis and increase in the number of major R&D initiatives in areas such as proteomics, metabolomics and transcriptomics are expected to propel adoption of NGS in the coming years. Rapid pace of technology advancements and development of novel NGS products aimed at increasing throughput, enhancing accuracy and reducing costs are also poised to benefit market prospects in the near term.

As stated by the new market research report on Next Generation Sequencers, the United States represents the largest market worldwide. Presence of advanced healthcare technology framework, increasing R&D investments in proteomic and genomic sequence determination for biomarkers research, and rapid reduction in sequencing cost per each base pair are instrumental in making the country the world’s largest market for next generation sequencing products. Asia-Pacific is poised to grow at the fastest CAGR of 15.1% over the analysis period due largely to the rapidly improving healthcare infrastructure, favorable government policies, and the increased willingness to use novel solutions and platforms.

Major players profiled in the report include Agilent Technologies Inc., Becton, Dickinson and Company, Shenzhen BGI Diagnosis Co. Ltd., Fluidigm Corporation, Illumina Inc., Oxford Gene Technology, Oxford Nanopore Technologies, Pacific Biosciences of California Inc., QIAGEN N.V., Roche Sequencing, Thermo Fisher Scientific Inc. and RainDance Technologies Inc., among others.

The research report titled “Next Generation Sequencers: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of market trends, issues, drivers, mergers, acquisitions and other strategic industry activities of global companies. The report provides market estimates and projections for all major geographic markets such as the United States, Canada, Japan, Europe (France, Germany, Italy, UK, Spain, Russia and Rest of Europe), Asia-Pacific (China, and Rest of Asia-Pacific), Latin America (Brazil, and Rest of Latin America) and Rest of World. End-use industries analyzed for the Global market includes Pharmaceuticals/Biotech; Industrial, and Government/Academia.

 

» View Complete Report Details

« Back